This section discusses ubiquitin pathway-targeting drugs and some of the strategies for the development as well as the potential utilization of RNF126, RNF168 and the CUL1 and SCF complex and its related factors for cancer therapy and diagnostics. This evidence concerns the gene RNF126 and cancer.